The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models

BACKGROUND/AIMS: The therapeutic options for metastatic neuroendocrine tumors (NETs) are limited. As PI3K signaling is often activated in NETs, we have assessed the effects of selective PI3Kp110α inhibition by the novel agent BYL719 on cell viability, colony formation, apoptosis, cell cycle, signali...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:PLoS One
Main Authors: Nölting, Svenja, Rentsch, Jakob, Freitag, Helma, Detjen, Katharina, Briest, Franziska, Möbs, Markus, Weissmann, Victoria, Siegmund, Britta, Auernhammer, Christoph J., Aristizabal Prada, Elke Tatjana, Lauseker, Michael, Grossman, Ashley, Exner, Samantha, Fischer, Christian, Grötzinger, Carsten, Schrader, Jörg, Grabowski, Patricia
Formato: Artigo
Idioma:Inglês
Publicado em: Public Library of Science 2017
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5553670/
https://ncbi.nlm.nih.gov/pubmed/28800359
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0182852
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados